AI-Driven Assessment of Antibody Developability for Faster and More Reliable Biologic Development
AI-Driven Antibody Manufacturability Prediction
Successful antibody development requires more than high target affinity.
Many promising antibody candidates encounter development challenges due to poor manufacturability, including low expression, aggregation, instability, high viscosity, or formulation difficulties.
Neoncorte Bio applies AI-driven protein engineering and developability assessment to identify manufacturability risks early and support the selection and optimization of antibody candidates with stronger commercial potential.
Why Antibody Manufacturability Matters
Manufacturability has become a critical factor in therapeutic antibody development.
Even antibodies with excellent biological activity may be difficult to manufacture, formulate, or scale if they exhibit unfavorable biophysical properties.
Early prediction of manufacturability can help reduce development risk, prioritize stronger candidates, and improve the efficiency of antibody discovery programs.
Even antibodies with excellent biological activity may be difficult to manufacture, formulate, or scale if they exhibit unfavorable biophysical properties.
Early prediction of manufacturability can help reduce development risk, prioritize stronger candidates, and improve the efficiency of antibody discovery programs.
Application Areas
-
Therapeutic Antibody Discovery
Prioritize antibody candidates with favorable developability profiles.
Benefit: Improved candidate selection before costly downstream development. -
Lead Optimization
Identify sequence modifications that may improve manufacturability while maintaining functional properties.
Benefit: Better balance between efficacy and manufacturability. -
Biopharmaceutical Development
Support selection of antibody candidates suitable for scalable manufacturing.
Benefit: Reduced development risk and improved production readiness. -
Antibody Engineering
Guide engineering efforts to reduce liabilities affecting manufacturing and formulation.
Benefit: More robust therapeutic candidates. -
Technology Licensing and Due Diligence
Evaluate developability characteristics during partnership or licensing activities.
Benefit: Additional confidence when selecting development candidates.
Common Developability Challenges
Antibody candidates may experience:
- Low recombinant expression
- Protein aggregation
- Poor solubility
- High solution viscosity
- Limited thermal stability
- Chemical instability
- Formulation challenges
- Difficult purification
- Reduced storage stability
- Manufacturing scalability issues
AI-Guided Antibody Manufacturability Prediction
Neoncorte Bio combines computational protein engineering with structural biology and machine learning to evaluate antibody developability before large-scale experimental investment.
Our computational workflow may incorporate:
- Antibody sequence analysis
- Structure-informed modeling
- Aggregation propensity prediction
- Solubility assessment
- Stability prediction
- Surface property analysis
- Machine learning
- Protein language models
- Multi-parameter optimization
- Design-Build-Test-Learn (DBTL) methodologies
- Results help prioritize antibody candidates for further characterization and optimization.
Manufacturability Properties We Assess
Depending on project requirements, our AI-guided workflows may evaluate:
- Recombinant expression potential
- Aggregation propensity
- Solubility
- Thermal stability
- Freeze-thaw stability
- Oxidation susceptibility
- Deamidation risk
- Surface hydrophobicity
- Charge distribution
- Viscosity-related properties
- Sequence liabilities
- Overall developability
- Assessments are tailored to the specific antibody format and intended manufacturing process.
Design-Build-Test-Learn (DBTL) Integration
Manufacturability prediction is most valuable when integrated into iterative antibody optimization.
Neoncorte Bio supports:
- Antibody sequence analysis
- AI-guided developability assessment
- Candidate prioritization
- Experimental validation
- Machine learning model refinement
- Successive Design-Build-Test-Learn (DBTL) cycles
What Neoncorte Bio Delivers
- AI-guided antibody developability assessment
- Manufacturability prediction
- Sequence liability analysis
- Aggregation and solubility assessment
- Multi-parameter antibody optimization
- Structure-informed engineering support
- Design-Build-Test-Learn (DBTL) workflows
- Confidential B2B antibody engineering partnerships
Who We Work With
- Biopharmaceutical companies
- Therapeutic antibody developers
- Antibody discovery platforms
- Biotechnology startups
- CDMOs and CROs
- Pharmaceutical companies
- Academic translational research groups
- Investors performing technical due diligence
Frequently Asked Questions (FAQs)
Our platform harnesses advanced artificial intelligence and machine learning to design, optimize, and engineer proteins tailored to your specific requirements. Whether you need improved enzyme efficiency, novel protein functions, or tailored biotherapeutics, our solutions streamline the protein design process and reduce time-to-market.
Our services are ideal for biotechnology and pharmaceutical companies, academic research labs, industrial manufacturers, and any organization involved in protein-based product development. Applications include enzyme optimization, biocatalyst development, therapeutic protein design, and more.
The process begins with your input data, such as protein sequences, structural information, and desired functional attributes. Our AI algorithms then generate a library of potential protein variants and use predictive modeling to evaluate their stability, activity, and specificity. The top candidates are ranked and provided for further experimental validation, thereby reducing the number of required lab iterations.
Our platform is versatile and can be applied to a wide range of proteins, including enzymes, structural proteins, and therapeutic proteins. We can optimize existing proteins or design novel ones for applications in catalysis, biopharmaceuticals, diagnostics, and more.
Absolutely. We work closely with you to tailor our AI models and algorithms to your target proteins and desired outcomes. This includes integrating proprietary data and fine-tuning parameters to ensure that our platform delivers the most relevant and high-performing protein candidates for your application.
Our platform offers robust API support and standard data export formats (e.g., CSV, JSON) to seamlessly integrate with your Laboratory Information Management Systems (LIMS) and other data analytics pipelines. We also provide comprehensive onboarding and training to ensure a smooth adoption process.
Our models are trained on extensive datasets of protein interactions, structural data, and experimental results. We continuously refine our algorithms with real-world feedback to improve prediction accuracy. While our computational predictions are highly reliable, we recommend subsequent in vitro or in vivo validation to confirm the performance of the engineered proteins.
Yes, we provide collaborative support throughout the validation process. Our team can help design proof-of-concept studies and coordinate with your wet lab partners to verify the performance of our predicted protein variants.
We offer flexible pricing models based on the scope and duration of your project. Options include subscription-based plans for ongoing R&D, as well as project-specific pricing for one-off protein engineering campaigns. Please contact us for a personalized consultation and detailed quote.
Our dedicated customer support team is available to assist you at every stage—from initial onboarding and technical training to troubleshooting and ongoing optimization. We offer support via email, phone, and live chat, along with detailed documentation and a comprehensive FAQ section.
Improve Antibody Developability Before Manufacturing
Contact us to discuss your antibody manufacturability prediction project
Neoncorte Bio
Where AI Meets Biotechnology
Neoncorte Bio is at the forefront of the convergence between artificial intelligence and enzyme engineering. Our team comprises experts in computational biology, bioinformatics, and machine learning, all driven by a mission to accelerate innovation in enzyme design. By leveraging our advanced AI models, we provide unparalleled solutions that enhance efficiency, reduce costs, and push the boundaries of what's possible in enzyme engineering
Proud Member of Leading Global AI Programs
Neoncorte Bio is part of the NVIDIA Inception and Nebius for Startups programs — two of the world’s leading ecosystems for high-performance AI innovation. These partnerships strengthen our ability to deliver next-generation AI-driven protein, enzyme, and aptamer engineering.
-
As a member of NVIDIA Inception, Neoncorte Bio gains access to cutting-edge GPU technologies, expert guidance, and a global AI ecosystem that supports companies from prototype to production. The program empowers us to explore new AI opportunities and build high-performance biological design pipelines powered by NVIDIA’s world-class platform. -
Through Nebius for Startups, we gain access to high-performance compute infrastructure optimized for large-scale AI workloads, along with hands-on technical guidance and a strong community of innovative AI companies. Nebius enables us to train and deploy complex biological models more efficiently — accelerating enzyme, protein, and aptamer design while supporting rapid scaling of our R&D pipelines.
Publications
Scientific Publication of Neoncorte Bio Team
- Modification of natural enzymes to introduce new properties and enhance existing ones is a central challenge in bioengineering. This study is focused on the development of Taq polymerase mutants that show enhanced reverse transcriptase (RTase) activity while retaining other desirable properties such as fidelity, 5′-3′ exonuclease activity, effective deoxyuracil incorporation, and tolerance to locked nucleic acid (LNA)-containing substrates.
- The transcriptomic data are being frequently used in the research of biomarker genes of different diseases and biological states. The most common tasks there are the data harmonization and treatment outcome prediction. Both of them can be addressed via the style transfer approach. Either technical factors or any biological details about the samples which we would like to control (gender, biological state, treatment, etc.) can be used as style components.
- List of all Neoncorte Bio publications dedicated to Molecular Biology, Biotechnology, Artificial Intelligence and Artificial Neural Networks, published mostly by Nikolay Russkikh, CEO of Neoncorte Bio
Our Expertise in Action
With extensive experience in AI applications and software engineering tailored to the life sciences, we specialize in solving complex challenges and delivering innovative solutions for our customers. Our work demonstrates a deep understanding of cutting-edge technologies and their application in the real world.
Here are examples of the types of projects we have successfully delivered:
Here are examples of the types of projects we have successfully delivered:
- Automated NGS Data Analysis:Designed a production-grade solution for the automated processing, annotation, and analysis of Next-Generation Sequencing (NGS) data.
- Single-Cell Data Integration:Built state-of-the-art tools for integrating multimodal single-cell data, achieving recognition for technical excellence.
- Metagenomic Classification Algorithms:Developed advanced methods for classifying sequencing reads in metagenomics research.
- High-Throughput Image Processing Pipelines:Engineered an efficient pipeline to process millions of sequencing images with exceptional accuracy.
- Cell Counting via AI:Created a computer vision solution for precise cell counting in microphotography images, streamlining data analysis.
Get in touch with our team
Phone: +1-503-754-3958
Email: contact@neoncorte.com
Email: contact@neoncorte.com
© All Rights Reserved. Neoncorte Bio. 2024-2026
contact@neoncorte.com
contact@neoncorte.com